KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $9.4 million.

  • Neogenomics' Net Cash Flow rose 3568.84% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.8 million, marking a year-over-year decrease of 45485.62%. This contributed to the annual value of $24.5 million for FY2024, which is 6907.75% down from last year.
  • Neogenomics' Net Cash Flow amounted to $9.4 million in Q3 2025, which was up 3568.84% from -$191.4 million recorded in Q2 2025.
  • Neogenomics' 5-year Net Cash Flow high stood at $372.5 million for Q1 2021, and its period low was -$250.2 million during Q2 2021.
  • Its 5-year average for Net Cash Flow is -$4.6 million, with a median of -$2.9 million in 2022.
  • In the last 5 years, Neogenomics' Net Cash Flow skyrocketed by 133044.81% in 2023 and then crashed by 92610.59% in 2025.
  • Neogenomics' Net Cash Flow (Quarter) stood at -$26.9 million in 2021, then soared by 89.05% to -$2.9 million in 2022, then skyrocketed by 1330.45% to $36.2 million in 2023, then plummeted by 86.15% to $5.0 million in 2024, then skyrocketed by 86.69% to $9.4 million in 2025.
  • Its Net Cash Flow was $9.4 million in Q3 2025, compared to -$191.4 million in Q2 2025 and -$20.8 million in Q1 2025.